Urinary Microalbumin (HSA/MAU)
Urinary Microalbumin (HSA/MAU) antibody raw material for immunoassay development, reagent screening and rapid-test optimization. Source: Mouse; application: Early Kidney Injury / Diabetic Nephropathy Assessment.
Background
Albumin is one of the important plasma proteins. Under normal circumstances, the molecular weight of albumin is large and cannot cross the glomerular basement membrane. Therefore, in healthy people, the urine contains only very low concentration of albumin, which is less than 20mg per liter of urine.
In disease, the glomerular basement membrane is damaged, leading to changes in permeability. Any lesion that can cause increased glomerular basement membrane permeability can lead to albumin excretion.
At this point, albumin can enter the urine, and the concentration of albumin in the urine will continue to rise.
Clinical Significance
Urinary microalbumin assay reflects early renal disease and renal injury.
The pathologic increase was seen in diabetic nephropathy, hypertension, and preeclampsia.
In the early stage of microalbumin is the early signal and omen of nephropathy, at this time the kidney damage is still reversible, if it can be timely treated, which can stop or reverse the development process of nephropathy.
Urinary microalbumin test can be used as an indicator of renal function in systemic or local inflammatory reactions, such as early renal lesions caused by urinary tract infection.
Predictors of complications of acute pancreatitis;
The person that takes the medicine that has effect to kidney function also can detect uric microalbumin, facilitate early observation kidney function circumstance takes measure as early as possible.
Product Parameters
Performance is very good; double antibody sandwich method launched very early; flexible price; target market is turbidimetric market.
Code: RMMA4
| Material / Clone | Type | Code | Source | Application | Recommended Use |
|---|---|---|---|---|---|
| HSA/MAU Raw Material Set | Raw Material Set | RMMA4 | Mouse | EIA, LF | - |